<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36855314</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-8847</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Developing world bioethics</Title><ISOAbbreviation>Dev World Bioeth</ISOAbbreviation></Journal><ArticleTitle>La pobreza extrema es&#xa0;prioridad: Un argumento sobre la distribuci&#xf3;n equitativa de la vacuna contra el COVID-19 en Per&#xfa;.</ArticleTitle><Pagination><StartPage>102</StartPage><EndPage>106</EndPage><MedlinePgn>102-106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/dewb.12393</ELocationID><Abstract><AbstractText>La humanidad ya dispone de vacunas eficaces contra el COVID-19. En Per&#xfa; se administraron 86 millones de dosis para cubrir la demanda de 33 millones de peruanos. Para ello, se ha priorizado la vacunaci&#xf3;n en grupos clave: personal de salud, sujetos con condiciones de salud preexistentes y mayores de 65 a&#xf1;os. Sin embargo, dada la problem&#xe1;tica social y la situaci&#xf3;n de la salud p&#xfa;blica en Per&#xfa;, este trabajo defiende que la prioridad de la vacunaci&#xf3;n debe centrarse en la poblaci&#xf3;n que vive en extrema pobreza. El m&#xe9;todo utilizado fue una argumentaci&#xf3;n &#xe9;tica sobre la distribuci&#xf3;n de la vacuna contra el COVID-19 en Per&#xfa;. Esta argumentaci&#xf3;n se basa en el an&#xe1;lisis de la poblaci&#xf3;n peruana que vive en extrema pobreza, la cual presenta diferentes estratos de vulnerabilidad, y que, ante una eventual infecci&#xf3;n por SARS-CoV-2, se&#xa0;ir&#xed;an&#xa0;agravando&#xa0;uno tras otro, a trav&#xe9;s de un efecto en&#xa0;cascada. Este escenario dar&#xed;a lugar a nuevas vulnerabilidades de las ya existentes, causando mayores da&#xf1;os. Los esfuerzos de vacunaci&#xf3;n en esta poblaci&#xf3;n clave les brindar&#xed;a oportunidad de seguir encontrando formas de llevar alimentos a sus hogares, reduciendo significativamente el riesgo de contagio en su entorno y mitigando el efecto devastador de las enfermedades locales a las que ya est&#xe1; expuesta. Se plantean cuatro objeciones relacionadas con este argumento, con sus correspondientes respuestas. El acceso prioritario a la vacuna reducir&#xed;a significativamente el da&#xf1;o a las personas que viven en la extrema pobreza, haciendo prevalecer los principios de justicia y equidad.</AbstractText><CopyrightInformation>&#xa9; 2023 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yabar</LastName><ForeName>Carlos Augusto</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-9607-5693</Identifier></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Bioethics Program of FLACSO - Argentina (PAHO/WHO Collaborating Center for Bioethics) - Research Ethics Training Program funded by the Fogarty International Center</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dev World Bioeth</MedlineTA><NlmUniqueID>101120122</NlmUniqueID><ISSNLinking>1471-8731</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010568" MajorTopicYN="N" Type="Geographic">Peru</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply &amp; distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011203" MajorTopicYN="Y">Poverty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035862" MajorTopicYN="N">Vulnerable Populations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015276" MajorTopicYN="N">Health Care Rationing</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069576" MajorTopicYN="N">Health Equity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006292" MajorTopicYN="N">Health Priorities</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">Per&#xfa;</Keyword><Keyword MajorTopicYN="N">pobreza</Keyword><Keyword MajorTopicYN="N">vacunas</Keyword><Keyword MajorTopicYN="N">&#xe9;tica</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36855314</ArticleId><ArticleId IdType="doi">10.1111/dewb.12393</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34397560</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Development of a Practice Guideline for Discharge Opioid Prescribing After Major Colorectal Surgery.</ArticleTitle><Pagination><StartPage>1120</StartPage><EndPage>1128</EndPage><MedlinePgn>1120-1128</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002024</ELocationID><Abstract><AbstractText Label="BACKGROUND">Better alignment of opioid prescription quantities with patient need could help reduce excessive prescribing.</AbstractText><AbstractText Label="OBJECTIVE">The study sought to develop an institutional prescribing guideline based on defined opioid consumption patterns after inpatient colorectal operations.</AbstractText><AbstractText Label="DESIGN">This was a retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS">The study was conducted at a single tertiary care center.</AbstractText><AbstractText Label="PATIENTS">Patients who underwent elective major colorectal procedures between July 2018 and January 2019 were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The study measured prescription and consumption quantities measured as equianalgesic oxycodone 5-mg pills.</AbstractText><AbstractText Label="RESULTS">Patients were categorized into 3 groups based on consumption in the 24-hour period before discharge: tier 1 consumed 0 equianalgesic oxycodone 5-mg pills (n = 53), tier 2 consumed 0.1 to 3.0 equianalgesic oxycodone 5-mg pills (n = 25), and tier 3 consumed &gt;3.0 equianalgesic oxycodone 5-mg pills (n = 22). Average prescription quantity was 17.5 &#xb1; 10.5 equianalgesic oxycodone 5-mg pills (range, 0-78). Patients consumed a mean of 6.7 &#xb1; 10.9 equianalgesic oxycodone 5-mg pills after discharge and had 10.8 &#xb1; 10.2 equianalgesic oxycodone 5-mg pill excess, whereas 51% of patients consumed no pills. Opioid consumption was significantly different between each tier (p &lt; 0.001). A prescribing guideline was developed to satisfy the majority of patients: 0 equianalgesic oxycodone 5-mg pills if tier 1, 12 pills if tier 2, and 30 pills if tier 3. Tiered guideline adoption could reduce prescribed pills by 45% and excess pills per prescription by 73%. Patient history of IBD was independently associated with increased odds of exceeding the guideline (adjusted OR = 7.2 (95% CI, 1.6-32.6)).</AbstractText><AbstractText Label="LIMITATIONS">The study was limited by its single-center, retrospective design and that outpatient opioid consumption was self-reported.</AbstractText><AbstractText Label="CONCLUSIONS">Following hospital discharge after major colorectal surgery, more than half of patients consumed no opioid pills, and 62% of prescribed opioids were in excess. Outpatient opioid consumption was highly associated with inpatient opioid use in the 24 hours before discharge. Prospective validation of this prescribing guideline is needed, but adoption could reduce excessive prescribing. See Video Abstract at http://links.lww.com/DCR/B575.</AbstractText><AbstractText Label="DESARROLLO DE UNA GUA PRCTICA PARA LA PRESCRIPCIN DE OPIOIDES AL EGRESO DESPUS DE UNA CIRUGA COLORRECTAL MAYOR">ANTECEDENTES:Una mejor alineaci&#xf3;n de las cantidades de prescripci&#xf3;n de opioides con las necesidades del paciente podr&#xed;a ayudar a reducir la prescripci&#xf3;n excesiva.OBJETIVO:El estudio busc&#xf3; desarrollar una gu&#xed;a institucional de prescripci&#xf3;n basada en patrones definidos de consumo de opioides luego de cirug&#xed;as colorrectales hospitalarias.DISE&#xd1;O:Estudio de cohorte retrospectivo.ENTORNO CL&#xcd;NICO:El estudio se llev&#xf3; a cabo en un solo centro de atenci&#xf3;n terciaria.PACIENTES:Pacientes que se sometieron a procedimientos colorrectales mayores electivos entre julio de 2018 y enero de 2019.PRINCIPALES MEDIDAS DE RESULTADO:El estudio midi&#xf3; las cantidades de prescripci&#xf3;n y consumo medidas como p&#xed;ldoras de 5&#x2009;mg de oxicodona equianalg&#xe9;sica (EOP).RESULTADOS:Los pacientes se clasificaron en tres grupos seg&#xfa;n el consumo en el per&#xed;odo de 24 horas antes del egreso: el nivel 1 consumi&#xf3; 0 EOP (n = 53), el nivel 2 consumi&#xf3; 0,1-3 EOP (n = 25) y el nivel 3 consumi&#xf3; m&#xe1;s de 3 EOP (n = 22). La cantidad promedio de prescripci&#xf3;n fue 17,5 (&#xb1; 10,5) EOP (rango: 0-78). Los pacientes consumieron una media de 6,7 (&#xb1; 10,9) EOP posterior al egreso y tuvieron un exceso de 10,8 (&#xb1; 10,2) EOP, mientras que el 51% de los pacientes no consumieron p&#xed;ldoras. El consumo de opioides fue significativamente diferente entre cada nivel (p &lt;0,001). Se desarroll&#xf3; una gu&#xed;a de prescripci&#xf3;n para satisfacer a la mayor&#xed;a de los pacientes: 0 EOP del nivel 1, 12 EOP del nivel 2 y 30 EOP del nivel 3. La adquisici&#xf3;n de una gu&#xed;a escalonada podr&#xed;a reducir las p&#xed;ldoras recetadas en un 45% y el exceso de p&#xed;ldoras por receta en un 73%. El historial del paciente de enfermedad inflamatoria intestinal se asoci&#xf3; de forma independiente con un aumento de las probabilidades de superar la gu&#xed;a (ORa 7,2; IC del 95%: 1,6-32,6).LIMITACIONES:El estudio estuvo limitado por su dise&#xf1;o retrospectivo de un solo centro y por el consumo de opioides del paciente ambulatorio el cual fue autoinformado.CONCLUSIONES:Tras el egreso hospitalario de una cirug&#xed;a colorrectal mayor, m&#xe1;s de la mitad de los pacientes no consumieron pastillas opioides y el 62% de los opioides prescritos estaban en exceso. El consumo de opioides como paciente ambulatorio estuvo altamente asociado con el uso de opioides como paciente hospitalizado en las 24 horas previas al egreso. Se necesita una validaci&#xf3;n prospectiva de esta gu&#xed;a de prescripci&#xf3;n, pero la adopci&#xf3;n podr&#xed;a reducir la prescripci&#xf3;n excesiva. Consulte Video Resumen en http://links.lww.com/DCR/B575.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Susanna S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavao</LastName><ForeName>M Richard</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harnsberger</LastName><ForeName>Cristina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturrock</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maykel</LastName><ForeName>Justin A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alavi</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>CD35PMG570</RegistryNumber><NameOfSubstance UI="D010098">Oxycodone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="N">Digestive System Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016134" MajorTopicYN="N">Organizational Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010098" MajorTopicYN="N">Oxycodone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34397560</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002024</ArticleId><ArticleId IdType="pii">00003453-202109000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann Intern Med. 2017;167:293&#x2013;301.</Citation></Reference><Reference><Citation>Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8:171&#x2013;183.</Citation></Reference><Reference><Citation>Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ. 2018;360:j5790.</Citation></Reference><Reference><Citation>Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152:1066&#x2013;1071.</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2019). Results from the 2018 National Survey on Drug Use and Health: detailed tables. Accessed September 2, 2019. https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables</Citation></Reference><Reference><Citation>Neuman MD, Bateman BT, Wunsch H. Inappropriate opioid prescription after surgery. Lancet. 2019;393:1547&#x2013;1557.</Citation></Reference><Reference><Citation>Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use: United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66:265&#x2013;269.</Citation></Reference><Reference><Citation>Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152:e170504.</Citation></Reference><Reference><Citation>Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: a retrospective cohort study. Arch Intern Med. 2012;172:425&#x2013;430.</Citation></Reference><Reference><Citation>Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain: United States, 2016. MMWR Recomm Rep. 2016;65:1&#x2013;49.</Citation></Reference><Reference><Citation>Commonwealth of Massachusetts Board of Registration in Medicine Quality and Patient Safety Division. Advisory: best practices in prescribing opioids. Accessed September 10, 2019. https://www.mass.gov/files/documents/2019/09/05/opioid-advisory.pdf</Citation></Reference><Reference><Citation>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists&#x2019; Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17:131&#x2013;157.</Citation></Reference><Reference><Citation>Michigan Opioid Prescribing Engagement Network. Prescribing recommendations. Accessed April 1, 2020. https://michigan-open.org/prescribing-recommendations/</Citation></Reference><Reference><Citation>Hill MV, Stucke RS, Billmeier SE, Kelly JL, Barth RJ Jr. Guideline for discharge opioid prescriptions after inpatient general surgical procedures. J Am Coll Surg. 2018;226:996&#x2013;1003.</Citation></Reference><Reference><Citation>Glaser GE, Kalogera E, Kumar A, et al. Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery. Gynecol Oncol. 2020;157:476&#x2013;481.</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services. Opioid oral morphine milligram equivalent: (MME) conversion factors. Accessed October 3, 2018. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Oral-MME-CFs-vFeb-2018.pdf</Citation></Reference><Reference><Citation>University of North Carolina Health Care Guideline. Opiate equianalgesic dosing chart. 2018. Accessed October 3, 2018. https://www.med.unc.edu/aging/files/2018/06/Analgesic-Equivalent-Chart.pdf</Citation></Reference><Reference><Citation>Thiels CA, Anderson SS, Ubl DS, et al. Wide variation and overprescription of opioids after elective surgery. Ann Surg. 2017;266:564&#x2013;573.</Citation></Reference><Reference><Citation>Eid AI, DePesa C, Nordestgaard AT, et al. Variation of opioid prescribing patterns among patients undergoing similar surgery on the same acute care surgery service of the same institution: time for standardization? Surgery. 2018;164:926&#x2013;930.</Citation></Reference><Reference><Citation>Tan WH, Yu J, Feaman S, et al. Opioid medication use in the surgical patient: an assessment of prescribing patterns and use. J Am Coll Surg. 2018;227:203&#x2013;211.</Citation></Reference><Reference><Citation>Tan WH, Feaman S, Milam L, et al. Postoperative opioid prescribing practices and the impact of the hydrocodone schedule change. Surgery. 2018;164:879&#x2013;886.</Citation></Reference><Reference><Citation>Howard R, Fry B, Gunaseelan V, et al. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surg. 2019;154:e184234.</Citation></Reference><Reference><Citation>Fujii MH, Hodges AC, Russell RL, et al. Post-discharge opioid prescribing and use after common surgical procedure. J Am Coll Surg. 2018;226:1004&#x2013;1012.</Citation></Reference><Reference><Citation>Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS One. 2016;11:e0147972.</Citation></Reference><Reference><Citation>Bartels K, Mahoney K, Raymond KM, et al. Opioid and non-opioid utilization at home following gastrointestinal procedures: a prospective cohort study. Surg Endosc. 2020;34:304&#x2013;311.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33373357</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1665-1731</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>4</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Archivos de cardiologia de Mexico</Title><ISOAbbreviation>Arch Cardiol Mex</ISOAbbreviation></Journal><ArticleTitle>[Cardiorenal syndrome: Clinical and echocardiographic aspects].</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>510</EndPage><MedlinePgn>503-510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/ACM.20000087</ELocationID><Abstract><AbstractText>El s&#xed;ndrome cardiorrenal (SCR) es un trastorno en el que intervienen el coraz&#xf3;n y los ri&#xf1;ones, interactuando y produciendo una disfunci&#xf3;n entre ellos en forma aguda o cr&#xf3;nica. Existen diferentes fenotipos cl&#xed;nicos bien identificados como &#xab;des&#xf3;rdenes del coraz&#xf3;n y ri&#xf1;&#xf3;n en los que la disfunci&#xf3;n aguda o cr&#xf3;nica en un &#xf3;rgano induce la disfunci&#xf3;n aguda o cr&#xf3;nica del otro&#xbb;. La alta incidencia de morbimortalidad cardiovascular presente en los pacientes con enfermedad renal cr&#xf3;nica terminal (ERCT), en especial la insuficiencia cardiaca (IC), origina inicialmente una lesi&#xf3;n mioc&#xe1;rdica que conlleva remodelamiento ventricular, lo cual induce a la activaci&#xf3;n de mecanismos compensadores, entre los cuales el ri&#xf1;&#xf3;n es pieza fundamental, ya que regula la homeostasis hidroelectrol&#xed;tica y as&#xed; el volumen circulante, siendo esto en la etapa dial&#xed;tica m&#xe1;s evidente. Los cambios funcionales y anat&#xf3;micos cardiovasculares que se producen en estos pacientes son muy prevalentes e incluyen las interacciones hemodin&#xe1;micas del coraz&#xf3;n y los ri&#xf1;ones en la insuficiencia cardiaca, y el impacto de la enfermedad ateroscler&#xf3;tica en ambos sistemas de &#xf3;rganos. Tambi&#xe9;n describimos estrategias diagn&#xf3;sticas y terap&#xe9;uticas aplicables al s&#xed;ndrome cardiorrenal, que determinan la importancia de la ecocardiograf&#xed;a como modelo de diagn&#xf3;stico &#xfa;til. Finalmente, se analizan las posibilidades de tratamiento y la remisi&#xf3;n de las alteraciones funcionales cardiacas con el trasplante renal en los pacientes con ERCT. Cardiorenal syndrome (CRS) is a disorder in which the heart and kidneys are involved, interacting and producing a dysfunction between them in an acute or chronic way. There are different clinical phenotypes well identified as &#x201c;heart and kidney disorders in which acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other&#x201d;. The high incidence of cardiovascular morbimortality in patients with chronic terminal kidney disease (CKD), especially heart failure (HF), initially causes a myocardial lesion that leads to ventricular remodeling, which induces the activation of compensatory mechanisms, among which the kidney is a fundamental part since it regulates the hydroelectrolytic homeostasis and thus the circulating volume, being this in the dialytic stage more evident. The functional and anatomical changes at cardiovascular level that occur in these patients are very prevalent, and include hemodynamic interactions of the heart and kidneys in heart failure and the impact of atherosclerotic disease in both organ systems. We also describe diagnostic and therapeutic strategies applicable to cardiorenal syndrome, which determine the importance of echocardiography as a useful diagnostic model. Finally, we analyze the possibilities of treatment and remission of cardiac functional alterations with renal transplantation in patients with T-CKD.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2020 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alprecht-Quiroz</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Hospital Luis Vernaza, Guayaquil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfa;&#xf1;iga-Pineda</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a, Hospital Luis Vernaza, Guayaquil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Juan Tanca Marengo, Guayaquil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Ciencia M&#xe9;dicas, Universidad de Guayaquil, Guayaquil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara-Ter&#xe1;n</LastName><ForeName>Joffre J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Juan Tanca Marengo, Guayaquil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#xe1;ceres-Vinueza</LastName><ForeName>Silvia V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Facultad de Ciencia M&#xe9;dicas, Universidad de Guayaquil, Guayaquil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Vera</LastName><ForeName>Yan C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Facultad de Ciencia M&#xe9;dicas, Universidad de Guayaquil, Guayaquil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital General Luis Vernaza, Guayaquil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Investigaci&#xf3;n y Docencia, Sociedad Ecuatoriana de Cardiolog&#xed;a, N&#xfa;cleo Guayas. Ecuador.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome cardiorrenal: aspectos cl&#xed;nicos y ecocardiogr&#xe1;ficos.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Arch Cardiol Mex</MedlineTA><NlmUniqueID>101126728</NlmUniqueID><ISSNLinking>1665-1731</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D059347" MajorTopicYN="N">Cardio-Renal Syndrome</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="Y">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspectos ecocardiogr&#xe1;ficos</Keyword><Keyword MajorTopicYN="N">Cardiorenal syndrome</Keyword><Keyword MajorTopicYN="N">Diastolic function</Keyword><Keyword MajorTopicYN="N">Echocardiographic aspects</Keyword><Keyword MajorTopicYN="N">Funci&#xf3;n diast&#xf3;lica</Keyword><Keyword MajorTopicYN="N">Funci&#xf3;n sist&#xf3;lica</Keyword><Keyword MajorTopicYN="N">Hipertrofia ventricular izquierda</Keyword><Keyword MajorTopicYN="N">Kidney transplant</Keyword><Keyword MajorTopicYN="N">Left ventricular hypertrophy</Keyword><Keyword MajorTopicYN="N">Systolic function</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome cardiorrenal</Keyword><Keyword MajorTopicYN="N">Trasplante renal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>17</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33373357</ArticleId><ArticleId IdType="doi">10.24875/ACM.20000087</ArticleId><ArticleId IdType="pii">j90/4/503</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31860182</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Biomedica : revista del Instituto Nacional de Salud</Title><ISOAbbreviation>Biomedica</ISOAbbreviation></Journal><ArticleTitle>Extensively resistant tuberculosis, Colombia, 2006-2016.</ArticleTitle><Pagination><StartPage>707</StartPage><EndPage>714</EndPage><MedlinePgn>707-714</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.4842</ELocationID><Abstract><AbstractText>Introducci&#xf3;n. La tuberculosis extremadamente resistente a los medicamentos (TB-XDR) es el resultado de deficiencias en la administraci&#xf3;n del tratamiento y en la prevenci&#xf3;n de la transmisi&#xf3;n de la enfermedad; adem&#xe1;s, es un reto para los programas nacionales de control de la tuberculosis. Objetivo. Describir las caracter&#xed;sticas cl&#xed;nicas y epidemiol&#xf3;gicas de los casos de TB-XDR diagnosticados en Colombia. Materiales y m&#xe9;todos. Se trata de un estudio de serie de casos, de pacientes con diagn&#xf3;stico de TB-XDR, de 2006 a 2016 en Colombia. Las fuentes de informaci&#xf3;n fueron el formato &#xfa;nico de vigilancia y la base de datos del Laboratorio Nacional de Referencia. Se analizaron las variables: entidad territorial de procedencia, sexo, edad, r&#xe9;gimen de afiliaci&#xf3;n, forma de tuberculosis, coinfecci&#xf3;n tuberculosis-HIV, patr&#xf3;n de sensibilidad a los f&#xe1;rmacos de segunda l&#xed;nea y resultado (vivo o muerto). Resultados. En el per&#xed;odo de estudio, se diagnosticaron 51 casos de TB-XDR, 28 hombres y 23 mujeres, con un promedio anual de cinco casos. En los departamentos de Antioquia, Valle del Cauca y Atl&#xe1;ntico, se presentaron 46 (90 %) de los casos. El rango de edad fue de 5 a 81 a&#xf1;os y, la mediana, de 40 a&#xf1;os. De los 51 pacientes, 32 (63 %) estaban afiliados al r&#xe9;gimen subsidiado de salud y 46 (90 %) presentaron tuberculosis pulmonar; de los 22 a quienes se les practic&#xf3; la prueba para HIV, en tres (13,6 %) hab&#xed;a coinfecci&#xf3;n con HIV, y 29 (57 %) murieron. Los f&#xe1;rmacos a los cuales hubo mayor resistencia, fueron ofloxacina en 45 (88 %) casos y amikacina en 43 (84 %). Conclusi&#xf3;n. La TB-XDR se present&#xf3; principalmente en formas pulmonares, lo cual aumenta la probabilidad de transmisi&#xf3;n en la comunidad y se refleja en la aparici&#xf3;n de tuberculosis resistente en menores de 15 a&#xf1;os. La poblaci&#xf3;n m&#xe1;s afectada es la econ&#xf3;micamente activa, con una gran mortalidad. El Programa Nacional de Prevenci&#xf3;n y Control de la Tuberculosis debe generar estrategias para evitar la propagaci&#xf3;n de cepas resistentes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zabaleta</LastName><ForeName>Angie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Micobacterias, Direcci&#xf3;n Redes en Salud P&#xfa;blica, Instituto Nacional de Salud, Bogot&#xe1;, D.C., Colombia. azabaleta@ins.gov.co.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llerena</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Serie de casos: tuberculosis extremadamente resistente a drogas en Colombia, 2006-2016.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Biomedica</MedlineTA><NlmUniqueID>8205605</NlmUniqueID><ISSNLinking>0120-4157</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054908" MajorTopicYN="N">Extensively Drug-Resistant Tuberculosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="INTRODUCTION:">Extensively drug-resistant tuberculosis (XDR-TB) is a result of deficiencies in the administration of treatment and transmission of the disease, being a challenge for national programs of tuberculosis control.</AbstractText><AbstractText Label="OBJECTIVE:">To describe the clinical and epidemiological characteristics of the cases diagnosed in Colombia.</AbstractText><AbstractText Label="MATERIALS AND METHODS:">Case series study, performed on people diagnosed with XDRTB during 2006 to 2016 in Colombia. Information source: unique surveillance format and database of the national reference laboratory. The variables territorial entity of origin, gender, age, affiliation regime, form of tuberculosis, tuberculosis-HIV coinfection, sensitivity pattern to second line drugs and live/dead outcome were analyzed.</AbstractText><AbstractText Label="RESULTS:">In this period, 51 XDR-TB cases have been diagnosed, with an annual average of five cases. Antioquia, Valle del Cauca and Atl&#xe1;ntico present 90% (46) of cases. Age range: 5 to 81 years, median: 40 years. There were 28 men (55%) of the cases. Subsidized affiliation regime: 63% (32/51). Pulmonary form: 90% (46/51). TB-HIV coinfection: 13.6% (3/22). The drugs with greater resistance: ofloxacin 90% (45/51) and amikacin 86% (43/51). Dead unlink: 57% (29/51).</AbstractText><AbstractText Label="CONCLUSION:">XDR-TB occurred mainly in pulmonary forms increasing the probability of transmission in the community, which is reflected in the appearance of resistance in children under 15 years of age. The most affected population is economically active, with high mortality. The national program of tuberculosis control must generate strategies to avoid the spread of resistance that is affecting children and the economically active population, with high mortality.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mycobacterium tuberculosis</Keyword><Keyword MajorTopicYN="N">extensively drug-resistant tuberculosis</Keyword><Keyword MajorTopicYN="N">pulmonary</Keyword><Keyword MajorTopicYN="N">tuberculosis multidrug-resistant</Keyword><Keyword MajorTopicYN="N">Colombia</Keyword></KeywordList><CoiStatement><b>Conflicto de intereses:</b> Los autores del presente art&#xed;culo no tienen ning&#xfa;n tipo de conflicto de intereses financieros, acad&#xe9;micos o personales, que puedan afectar la validez del estudio.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31860182</ArticleId><ArticleId IdType="pmc">PMC7363346</ArticleId><ArticleId IdType="doi">10.7705/biomedica.4842</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farga V, Caminero J. Tuberculosis. Tercera edici&#xf3;n. Santiago y Buenos Aires: Editorial Mediterr&#xe1;neo; 2010.</Citation></Reference><Reference><Citation>World Health Organization  . Global tuberculosis report. 2017.  [10 de octubre del 2018].  Disponible en:  http://www.who.int/tb/publications/global_report/es/</Citation></Reference><Reference><Citation>Mendoza A, Gotuzzo E. Tuberculosis extremadamente resistente (TB-XDR): historia y situaci&#xf3;n actual. Acta M&#xe9;dica Peruana. 2008;25:236&#x2013;246.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Eliminaci&#xf3;n de la tuberculosis extremadamente resistente (XDR TB)  [noviembre 20 del 2018].  Disponible en:  http://www.cdc.gov/tb/esp/publications/factsheets/pdf/xdrtbspanish.pdf.</Citation></Reference><Reference><Citation>Instituto Nacional de Salud  . Informe del evento tuberculosis farmacorresistente, Colombia. 2016.  [10 de octubre de 2018].  Disponible en:  http://www.ins.gov.co/ buscador-eventos/Informesdeevento/Tuberculosis%20farmacorresistente%202016.pdf.</Citation></Reference><Reference><Citation>Llerena C, Zabaleta A, Valbuena A, Murcia M. Prevalencia de la resistencia de Mycobacterium tuberculosis a quinolonas y f&#xe1;rmacos inyectables en Colombia, 2012-2013. Biom&#xe9;dica. 2017;37:96&#x2013;103. doi: 10.7705/biomedica.v37i2.3204.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v37i2.3204</ArticleId><ArticleId IdType="pubmed">28527253</ArticleId></ArticleIdList></Reference><Reference><Citation>Organismo Andino de Salud. Convenio Hip&#xf3;lito Unanue . Gu&#xed;a t&#xe9;cnica para el diagn&#xf3;stico bacteriol&#xf3;gico de la tuberculosis - Parte 3: pruebas de sensibilidad. Primera edici&#xf3;n. Lima: ORAS-CONHU; 2017.</Citation></Reference><Reference><Citation>Instituto Nacional de Salud  Informe del evento tuberculosis, Colombia. 2016.  [10 de octubre de 2018].  Disponible en:  http://www.ins.gov.co/buscador-eventos/Informesdeevento/Tuberculosis%20%202016.pdf.</Citation></Reference><Reference><Citation>Navas E, Moreno S. Tuberculosis multirresistente y extremadamente resistente. Rev Esp Sanid Penit. 2010;12:91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23128566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez R, Lupercio A, Hidalgo G, Le&#xf3;n S, Salazar J. Calidad de vida relacionada con la salud y trabajo en pacientes con tuberculosis en Guadalajara (M&#xe9;xico) Salud Barranquilla. 2013;29:13&#x2013;21.</Citation></Reference><Reference><Citation>Giraldo N, Valencia D, Cardona J. Calidad de vida relacionada con la salud en tuberculosis: revisi&#xf3;n sistem&#xe1;tica y metan&#xe1;lisis. Infectio. 2018;22:124&#x2013;130.</Citation></Reference><Reference><Citation>Zabaleta A, Llerena C, Valbuena A. Vigilancia por laboratorio de la tuberculosis resistente en menores de 15 a&#xf1;os, Colombia 2010 a 2015. Biom&#xe9;dica. 2018:39&#x2013;39. doi: 10.7705/biomedica.v39i3.4258.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v39i3.4258</ArticleId><ArticleId IdType="pubmed">31529820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C, Schaaf H. Manejo de la tuberculosis resistente a medicamentos. Int J Tuberc Lung Dis. 2010;14:672&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">20487603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornejo J, P&#xe9;rez J. Meningitis tuberculosa en ni&#xf1;os: una revisi&#xf3;n de aspectos cl&#xed;nicos, de laboratorio, epidemiol&#xf3;gicos y terap&#xe9;uticos y de la utilidad de la vacunaci&#xf3;n con BCG. Iatreia. 2010;23:250&#x2013;258.</Citation></Reference><Reference><Citation>Del Castillo H, Mendoza A, Saravia J, Somocurcio J. Epidemia de tuberculosis multidrogo resistente y extensivamente resistente a drogas (TB MDR/XDR) en el Per&#xfa;: situaci&#xf3;n y propuestas para su control. Rev. Per&#xfa; Med Exp Salud P&#xfa;blica. 2009;26:380&#x2013;386.</Citation></Reference><Reference><Citation>Ram&#xed;rez M, Men&#xe9;ndez A, Noguerado A. Tuberculosis extrapulmonar, una revisi&#xf3;n. Rev Esp Sanid Penit. 2015;17:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennassiri W, Jaouhari S, Cherki W, Charof R, Filali-Maltouf A, Lahlou O. Extensively drugresistant tuberculosis (XDR-TB) in Morocco. J Glob Antimicrob Resist. 2017;11:75&#x2013;80. doi: 10.1016/j.jgar.2017.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2017.07.002</ArticleId><ArticleId IdType="pubmed">28743645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunny G. Comparison of extremely drug resistant tuberculosis versus multidrug resistanttuberculosis patients attending a tertiary care center delivering directly observed treatment short plus regime. Int J Sci Stud. 2017;5:189&#x2013;194. doi: 10.17354/ijss/2017/293.</Citation><ArticleIdList><ArticleId IdType="doi">10.17354/ijss/2017/293</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaver J. Caracter&#xed;sticas cl&#xed;nicas y epidemiol&#xf3;gicas de pacientes con tuberculosis extremadamente resistente del hospital nacional Hip&#xf3;lito Unanue, Lima, 2013-2017. Lijma: Universidad Privada San Juan Bautista; 2018.</Citation></Reference><Reference><Citation>Haro F. Caracter&#xed;sticas sociodemogr&#xe1;ficas de los pacientes diagnosticados con tuberculosis pulmonar MDR y XDR en el complejo hospitalario PNP &#x201c;Luis N. S&#xe1;enz&#x201d; durante el periodo: julio 2016 a junio 2018. Lima: Universidad Ricardo Palma; 2019.</Citation></Reference><Reference><Citation>Organizaci&#xf3;n Mundial de la Salud  Estrategia Fin a la TB: objetivos e indicadores.  [20 de noviembre de 2018].  Disponible en:  https://www.who.int/tb/strategy/end-tb/es/</Citation></Reference><Reference><Citation>Ministerio de Salud y Protecci&#xf3;n Social  Plan estrat&#xe9;gico &#x201c;Hacia el fin de la tuberculosis&#x201d;, Colombia 2016-2025.  [20 de noviembre de 2018].  Disponible en  http://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/INTOR/Plan-estrategicofin-tuberculosis-colombia-2016-2025.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34233390</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-3164</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>1990</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Veterinary dermatology</Title><ISOAbbreviation>Vet Dermatol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Long Acting Oxytetracycline in the Treatment and Control of Bovine Dermatophilosis.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>84</EndPage><MedlinePgn>79-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-3164.1990.tb00083.x</ELocationID><Abstract><AbstractText>Abstract- Fifty-two cattle on two ranches in St. Kitts were divided into initial treatment and control groups, matched as closely as possible by age, sex and extent of dermatophilosis. Nine unaffected animals were included. The initial treatment group was given long-acting oxytetracycline at the rate of 20 mg.kg<sup>-1</sup> . After 4 weeks the control group was similarly treated. The cattle were observed at weekly intervals for a total of 6 weeks. In each group there was a pronounced decrease in the extent of the disease after treatment. This was most apparent in lightly affected animals and on the trunk. Lesions tended to persist in the tick predilection sites and extremities. Complete recovery occurred in 8 (21 per cent) of cattle. The disease tended to recur in treated animals particularly on one of the ranches in which a low standard of husbandry prevailed. On the other ranch improvements in tick control and feeding were associated with a continuing low level of infection. The results show that long-acting oxytetracycline can be used to conveniently halt outbreaks of dermatophilosis and allow time for changes in management designed to reduce recurrence of the disease. R&#xe9;sum&#xe9;- 52 bovins pr&#xe9;sents sur 2 ranchs &#xe0; Saint-Kitts, ont &#xe9;t&#xe9; divis&#xe9;s en groupes d'animaux trait&#xe9;s et en groupe d'animaux t&#xe9;moins, r&#xe9;partis aussi minutieusement que possible selon l'&#xe2;ge, le sexe et l'extension de la dermatophilose. Le groupe des animaux trait&#xe9;s a re&#xe7;u de l'oxyt&#xe9;tracycline-retard &#xe0; la dose de 20 mg.kg<sup>-1</sup> . Apr&#xe8;s 4 semaines, le groupe d'animaux t&#xe9;moins fut trait&#xe9; de la m&#xea;me mani&#xe8;re. Les bovins furent observ&#xe9;s une fois par semaine pendant une dur&#xe9;e totale de 6 semaines. Dans chaque groupe, il y eut une baisse sensible de l'extension de la maladie apr&#xe8;s le traitement. Ce fut le plus manifeste sur des animaux l&#xe9;g&#xe8;rement atteints et sur le tronc. Les l&#xe9;sions ont tendu &#xe0; persister sur les sites de pr&#xe9;dilection des tiques et sur les extr&#xe9;mit&#xe9;s. Une gu&#xe9;rison compl&#xe8;te fut not&#xe9;e sur 8 (21%) des bovins. Les maladies tendaient &#xe0; r&#xe9;cidiver sur les animaux trait&#xe9;s, principalement dans l'un des ranchs, o&#xf9; les conditions d'entretien &#xe9;taient d'un niveau m&#xe9;diocre. Dans l'autre ranch, des am&#xe9;liorations dans l'erradication des tiques et dans l'alimentation ont &#xe9;t&#xe9; associ&#xe9;es avec la persistance d'un niveau faible d'infection. Les r&#xe9;sultats montrent que l'oxyt&#xe9;tracycline retard peut &#xea;tre utilis&#xe9;e pour &#xe1;rr&#xea;ter commod&#xe9;ment les pouss&#xe9;es de dermatophilose et laisser du temps pour modifier les m&#xe9;thods afin de r&#xe9;cluire la r&#xe9;cidive de la maladie. Zusammenfassung- 52 Rinder in zwei Betrieben auf St. Kitts wurden in je eine Erstbehandlungs-und eine Kontrollgruppe aufgeteilt, die m&#xd6;glichst &#xe4;hnlich in Alter, Geschlecht und Auspr&#xe4;gungsgrad der Dermatophilose waren. Neun dieser Tiere waren nicht erkrankt. Die Erstbehandlungsgruppe erhielt ein Langzeit-Oxytetracyclin in der Dosierung von 20mg.kg<sup>-1</sup> . Nach 4 Wochen wurde die Kontrollgruppe nach dem gleichen Schema behandelt. Die Tiere wurden &#xfc;ber einen Zeitraum von sechs Wochen in w&#xd6;chentlichen Abst&#xe4;nden untersucht. In beiden Gruppen besserte sich der Schweregrad der Erkrankung nach Therapie deutlich, besonders bei den nur leicht befallenen Tieren und bei L&#xe4;sionen im Stammbereich. Dagegen neigten die Ver&#xe4;nderungen an den Pr&#xe4;dilektionsstellen f&#xfc;r Zecken und an den Gliedma&#xdf;en zur Persistenz. Acht der Tiere (21%) wurden v&#xd6;llig wiederhergestellt. Die Erkrankung neigte aber bei den therapierten Tieren zu Rezidiven, vor allem in einem der Betriebe mit niedrigem Pflegeniveau. Nach den vorliegenden Untersuchungen ist die Verwendung von Langzeit-Oxytetracyclin ein brauchbares Mittel, um die Dermatophilose zum Stillstand zu bringen und neue Ausbr&#xfc;che zu verhindern, bis weitere &#xc4;nderungen im Management zur Verringerung der Rezidivrate getroffen worden sind. Resumen&#x2002; Cincuenta y dos vacas de 2 explotaciones en St. Kitts se dividieron en un grupo de tratamiento y un grupo de control. Ambos grupos contenian aproximadamente la misma distributi&#xf3;n de sexos y la dermatofilosis estaba extendida en igual medida. Se incluyeron 9 animales no afectados. Los animates del grupo de tratamiento inicial recibieron oxitetraciclina de acti&#xf3;n retardada a una dosis de 20mg.kg<sup>-1</sup> . Cuatro semanas m&#xe1;s tarde los animales del grupo de control recibieron el mismo tratamiento. Las vacas fueron observadas semanalmente durante 6 semanas. En cada grupo se produjo una marcada reducci&#xf3;n en la extensi&#xe9;n de la enfermedad despu&#xe9;s del tratamiento. Esto fue m&#xe1;s marcado en aquellos animales afectados s&#xf3;lo de forma leve en la regi&#xf3;n del tronco. Las lesiones tendian a persistir en las zonas de predilecti&#xf3;n de las garrapatas y en las extremidades. En ocho animales se observ&#xf3; una curati&#xf3;n completa (21%). La enfermedad tendia a recidivar en los animales tratados expecialmente en una de las explotaciones en la cual se manten&#xed;an unas condiciones de cr&#xed;a bastante desfavorables. En la otra explotaci&#xf3;n el control de garrapatas y una mejoria en la alimentati&#xf3;n aparecieron asociadas a un bajo nivel de presentaci&#xf3;n de la enfermedad. Estos resultados indican que la oxitetraciclina de acti&#xf3;n retardada puede utilizarse para controlar focos de dermatofilosis, produciendo remisiones que permiten mejorar el manejo de las explotaciones y evitar recidivas de la enfermedad.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Royal Veterinary College Hawkshead Lane North Mymms Hertfordshire, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Julian P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Royal Veterinary College Hawkshead Lane North Mymms Hertfordshire, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pragnell</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Veterinary College Hawkshead Lane North Mymms Hertfordshire, U.K.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vet Dermatol</MedlineTA><NlmUniqueID>9426187</NlmUniqueID><ISSNLinking>0959-4493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Caribbean</Keyword><Keyword MajorTopicYN="N">Cattle</Keyword><Keyword MajorTopicYN="N">Dermatophilosis</Keyword><Keyword MajorTopicYN="N">Oxytetracycline</Keyword><Keyword MajorTopicYN="N">ticks</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233390</ArticleId><ArticleId IdType="doi">10.1111/j.1365-3164.1990.tb00083.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lloyd, D. H., Sellers, K. C. Dermatophilus Infection in Animals and Man. London : Academic Press, 1976: 1-322.</Citation></Reference><Reference><Citation>Lloyd, D. H. The economic effects of bovine streptothriocosis. In: Lloyd, D. H., Sellers, K. C. eds. Dermatophilus Infection in Animals and Man. London : Academic Press, 1976: 274-91.</Citation></Reference><Reference><Citation>Lloyd, D. H. Immunology of dermatophilosis. Recent developments and prospects for control. Preventive Veterinary Medicine 1984; 2: 93-102.</Citation></Reference><Reference><Citation>Blancou, J. M. The treatment of infection by Dermatophilus congolensis with particular reference to the disease in cattle. In: Lloyd, D. H., Sellers, K. C. eds. Dermatophilus Infection in Animals and Man. London : Academic Press, 1976: 246-259.</Citation></Reference><Reference><Citation>Ilemobade, A. A. Clinical experiences in the use of chemotherapy for bovine dermatophilosis in Nigeria. Preventive Veterinary Medicine 1984; 2: 83-92.</Citation></Reference><Reference><Citation>Roberts, D. S. Chemotherapy of epidermal infection with Dermatophilus congolensis Journal of Comparative Pathology and Therapeutics 1967; 77: 129-36.</Citation></Reference><Reference><Citation>Blancou, J. M. Traitement de la streptothricose bovine par une injection unique d'antibiotique &#xe0; haute dose. Revue d'Elevage et de M&#xe9;decine V&#xe9;t&#xe9;rinaire des Pays Tropicaux 1969; 22: 35-40.</Citation></Reference><Reference><Citation>Ilemobade, A. A., Gyang, E. O., Bida, S. A., Addo, P. B. Cure of Dermatophilus congolensis infection in cattle by long-acting oxytetracycline. Research in Veterinary Science 1979; 27: 302-5.</Citation></Reference><Reference><Citation>Gbodi, R. A., Ndife, I. Some observations on chemotherapy of bovine dermatophilosis. British Veterinary Journal 1982; 138: 288-94.</Citation></Reference><Reference><Citation>Sarradin, P., Akakpo, A. J., Bornarel, P., Mohamadou, B. Essai de traitement de la dermatophilose bovine au Cameroun. Int&#xe9;r&#xe9;t de l'association antibio-tique-bain acaricide. Revue d'Elevage et de M&#xe9;decine V&#xe9;t&#xe9;rinaire des pays Tropicaux 1985; 38: 239-46.</Citation></Reference><Reference><Citation>Sanders, A. B., How, S. J., Lloyd, D. H., Hill, R. The effect of energy malnutrition in ruminants on experimental infection with Dermatophilus congolensis Journal of Comparative Pathology 1990; In press.</Citation></Reference><Reference><Citation>Oppong, E. N. W. The epidemiology of Dermatophilus infection of cattle in the Accra Plains of Ghana. In: Lloyd, D. H., Sellers, K. C. eds. Dermatophilus Infection in Animals and Man. London : Acdemic Press 1976: 17-32.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>